Zanidatamab(一种新型双特异性抗体)治疗局部晚期或转移性HER2表达或HER2扩增癌症:一项1期剂量递增和扩展研究
这项首次人体、多中心、1期剂量递增和扩展试验评估了zanidatamab在HER2表达或HER2扩增的局部晚期或转移性实体瘤患者中的安全性和抗肿瘤活性。第一部分(n=46)未达到最大耐受剂量,第二部分推荐剂量为20 mg/kg每2周一次,在83例可评估患者中确认客观缓解率为37%(95% CI 27.0-48.7)。研究支持HER2是包括胆道癌和结直肠癌在内的多种癌症组织学的可作用靶点。
要点
- 第一部分(n=46)未检测到剂量限制性毒性,未达到最大耐受剂量。
- 第二部分推荐剂量为20 mg/kg每2周一次。
- 第二部分83例可评估患者确认客观缓解率为37%(95% CI 27.0-48.7)。
核心结论
- 这些结果支持HER2是包括胆道癌和结直肠癌在内的多种癌症组织学的可作用靶点。
- Zanidatamab的评估在正在进行的研究中继续。
研究设计与样本
- 这项首次人体、多中心、1期剂量递增和扩展试验纳入年龄18岁及以上、预期寿命至少3个月、东部肿瘤协作组体能状态为0或1、已接受所有可用获批治疗的局部晚期或转移性HER2表达或HER2扩增的任何类型实体瘤患者。
- 第一部分主要目标是确定zanidatamab的最大耐受剂量、最佳生物剂量或推荐剂量,所有患者均纳入主要分析;第一部分遵循3+3剂量递增设计,包括不同静脉剂量(从5 mg/kg至30 mg/kg)和间隔(每1、2或3周)。
- 第二部分主要目标是评估zanidatamab单药治疗在实体瘤中的安全性和耐受性。
- 招募于2016年9月1日至2021年3月13日进行;第一部分n=46;第二部分n=86(胆道癌n=22;结直肠癌n=28;其他HER2表达或HER2扩增癌症(排除乳腺癌或胃食管癌)n=36)。
- 该试验注册于ClinicalTrials.gov(NCT02892123),第一部分和第二部分已完成;第三部分评估zanidatamab联合化疗,正在进行中。
主要发现
- 第一部分(n=46)未检测到剂量限制性毒性,未达到最大耐受剂量。
- 第二部分推荐剂量为20 mg/kg每2周一次。
- 第一部分最常见的治疗相关不良事件为腹泻(46例患者中24例[52%];均为1-2级)和输注反应(46例患者中20例[43%];均为1-2级)。
- 第二部分最常见的治疗相关不良事件为腹泻(86例患者中37例[43%];除1例患者外均为1-2级)和输注反应(86例患者中29例[34%];均为1-2级);132例患者中4例(3%)报告了共6例3级治疗相关不良事件。
- 第二部分83例可评估患者中31例(37%;95% CI 27.0-48.7)有确认的客观缓解;无治疗相关死亡。
关键数值与推荐
- 第二部分推荐剂量为20 mg/kg每2周一次。
- 第二部分83例可评估患者确认客观缓解率为37%(95% CI 27.0-48.7)。
- 132例患者中4例(3%)报告了共6例3级治疗相关不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HER2-targeted therapies have substantially improved outcomes for patients with HER2-positive breast and gastric or gastro-oesophageal junction cancers. Several other cancers exhibit HER2 expression or amplification, suggesting that HER2-targeted agents can have broader therapeutic impact. Zanidatamab is a humanised, bispecific monoclonal antibody directed against two non-overlapping domains of HER2. The aim of this study was to evaluate the safety and anti-tumour activity of zanidatamab across a range of solid tumours with HER2 expression or amplification. METHODS: This first-in-human, multicentre, phase 1, dose-escalation and expansion trial included patients aged 18 years and older, with a life expectancy of at least 3 months, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and locally advanced or metastatic, HER2-expressing or HER2-amplified solid tumours of any kind who had received all available approved therapies. The primary objectives of part 1 were to identify the maximum tolerated dose, optimal biological dose, or recommended dose of zanidatamab; all patients were included in the primary analyses. Part 1 followed a 3 + 3 dose-escalation design, including different intravenous doses (from 5 mg/kg to 30 mg/kg) and intervals (every 1, 2, or 3 weeks). The primary objective of part 2 was to evaluate the safety and tolerability of zanidatamab monotherapy in solid tumours. This trial is registered with ClinicalTrials.gov (NCT02892123), and parts 1 and 2 of the trial are complete. Part 3 of the study evaluates the use of zanidatamab in combination with chemotherapy and is ongoing. FINDINGS: Recruitment took place between Sept 1, 2016, and March 13, 2021. In Part 1 (n=46), no dose-limiting toxicities were detected and the maximum tolerated dose was not reached. The recommended dose for part 2 (n=22 for biliary tract cancer; n=28 for colorectal cancer; and n=36 for other HER2-expressing or HER2-amplified cancers excluding breast or gastro-oesophageal cancers; total n=86) was 20 mg/kg every 2 weeks. The most frequent treatment-related adverse events in part 1 of the study were diarrhoea (24 [52%] of 46 patients; all grade 1-2) and infusion reactions (20 [43%] of 46 patients; all grade 1-2). The most frequent treatment-related adverse events in part 2 of the study were diarrhoea (37 [43%] of 86 patients; all grade 1-2 except for one patient) and infusion reactions (29 [34%] of 86 patients; all grade 1-2). A total of six grade 3 treatment-related adverse events were reported in four (3%) of 132 patients. In part 2, 31 (37%; 95% CI 27·0-48·7) of 83 evaluable patients had a confirmed objective response. There were no treatment-related deaths. INTERPRETATION: These results support that HER2 is an actionable target in various cancer histologies, including biliary tract cancer and colorectal cancer. Evaluation of zanidatamab continues in ongoing studies. FUNDING: Zymeworks.
引用
- Meric-Bernstam F, Beeram M, Hamilton E, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022. PMID: 36400106. doi:10.1016/S1470-2045(22)00621-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。